Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Next Previous
X
Search
Trial Profile

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary) ; Aflibercept
  • Indications Diabetes mellitus; Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms HULK
  • Sponsors Clearside Biomedical

    • Most Recent Events

    • 13 Nov 2017 Results presented in a Clearside Biomedical media release.
    • 13 Nov 2017 According to a Clearside Biomedical media release, preliminary results were presented during the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.
    • 08 Nov 2017 According to a Clearside Biomedical media release, the company expects to report preliminary results from the trial on November 10th at the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top